(S)-4′-hydroxypropranolol causes product inhibition and dose-dependent bioavailability of propranolol enantiomers in the isolated perfused rat liver and in rat liver microsomes

Xenobiotica

Volumn 26, Issue 12, 1996, Pages 1249-1261

  Nand, R A ^a   Ghabrial, H ^a   Smallwood, R A ^a   Morgan, D J ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYPROPRANOLOL; 4-HYDROXYPROPRANOLOL; DRUG DERIVATIVE; PROPRANOLOL;

ANIMAL; ARTICLE; BIOAVAILABILITY; CHEMISTRY; HYDROXYLATION; IN VITRO STUDY; KINETICS; LIVER; LIVER MICROSOME; MALE; METABOLISM; RAT; SPRAGUE DAWLEY RAT; STEREOISOMERISM;

ANIMALS; BIOLOGICAL AVAILABILITY; HYDROXYLATION; KINETICS; LIVER; MALE; MICROSOMES, LIVER; PROPRANOLOL; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM;

EID: 0030345024     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.3109/00498259609047229     Document Type: Article

References (30)

1. BARGAR, E. M., WALLE, U. K., BAI, H. A. and WALLE, T., 1983, Quantitative metabolic fate of propranolol in the dog, rat, and hamster using radiotracer, high performance liquid chromatography, and gas chromatography-mass spectrometry techniques. Drug Metabolism and Disposition, 11, 266-272.
2. BARRETT, A. M. and CULLUM, V. A., 1968, The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. British Journal of Pharmacology, 34, 43-55.
3. 2 and cumene hydroperoxide-supported reactions. Drug Metabolism and Disposition, 24, 112-118.
4. COLANGELO, P. M., BLOUIN, R. A., STEINMETZ, J. E., MCNAMARA, P. J., DEMARIA, A. N. and WEDLUND, P. J., 1992, Age and propranolol stereoselective disposition in humans. Clinical Pharmacology and Therapeutics, 51, 489-194.
5. COLANGELO, P. M., BLOUIN, R. A., STEINMETZ, J. E., MCNAMARA, P. J., DEMARIA, A. N. and WEDLUND, P. J., 1992, Age and propranolol stereoselective disposition in humans. Clinical Pharmacology and Therapeutics, 51, 489-494.
6. EVANS, G. H. AND SHAND, D. G., 1973, Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clinical Pharmacology and Therapeutics, 14, 487-493.
7. GHABRIAL, H., NAND, R., STEAD, C. K., SMALLWOOD, R. A. and MORGAN, D. J., 1994, Product inhibition and dose-dependent bioavailability of propranolol in the isolated perfused rat liver preparation. Journal of Pharmaceutical Sciences, 83, 931-936.
8. ISHIDA, R., SUZUKI, K., MASUBUCHI, Y., NARIMATSU, S., FUJITA, S. and SUZUKI, T., 1992, Enzymatic basis for the non-linearity of hepatic elimination of propranolol in the isolated perfused rat liver. Biochemical Pharmacology, 44, 2281-2288.
9. JONES, D. B., MIHALY, G. W., SMALLWOOD, R. A., WEBSTER, L. K., MORGAN, D. J. and MADSEN, N. P., 1984, Differential effects of hypoxia on the disposition of propranolol and sodium taurocholate by the isolated perfused rat liver. Hepatology, 4, 461-466.
10. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
11. MACKICHAN, J. J., PYSZCZYNSKI, D. R. and JUSKO, W. J., 1980, Dose-dependent disposition of oral propranolol in normal subjects. Biopharmaceutics and Drug Disposition, 1, 159-166.
12. MASUBUCHI, Y., SUZUKI, K., FUJITA, S. and SUZUKI, T., 1992, A possible mechanism of the impairment of hepatic microsomal monooxygenase activities after multiple administration of propranolol in rats. Biochemical Pharmacology, 43, 757-762.
13. MASUBUCHI, Y., YAMAMOTO, L. A., UESAKA, M., FUJITA, S., NARIMATSU, S. and SUZUKI, T., 1993, Substrate stereoeselectivity and enantiomer/enantiomer interaction in propranolol metabolism in rat liver microsomes. Biochemical Pharmacology, 46, 1759-1765.
14. NELSON, W. L. and BARTELS, M. J., 1984, N-dealkylation of propranolol in rat, dog, and man - chemical and stereochemical aspects. Drug Metabolism and Disposition, 12, 345-352.
15. OATIS, J. J., RUSSELL, M. P., KNAPP, D. R. and WALLE, T., 1981, Ring-hydroxylated propranolol: synthesis and beta-receptor antagonist and vasodilating activities of the seven isomers. Journal of Medicinal Chemistry, 24, 309-314.
16. OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes 1. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370-2378.
17. PURVES, R. D., 1989, User's Guide to Minim 1.6, Department of Pharmacology, Medical School, University of Otago, Dunedin, New Zealand.
18. RING, J. A., GHABRIAL, H., CHING, M. S., SHULKES, A., SMALLWOOD, R. A. and MORGAN, D. J., 1995, Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver. Drug Metabolism and Disposition, 23, 190-196.
19. SCHENKMAN, J. B. and CINTI, D. L., 1978, Preparation of microsomes with calcium. In Methods in Enzymology, Biomembranes, Part C, 52, (New York: Academic Press), pp. 83-89.
20. SCHNECK, D. W. and PRITCHARD, J. F., 1981, The inhibition effect of propranolol pretreatment on its own metabolism in the rat. Journal of Pharmacology and Experimental Therapeutics, 218, 575-581.
21. SHAND, D. G. and RANGNO, R. E., 1972, The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacology, 7, 159-168.
22. SILBER, B. M., HOLFORD, N. H. and RIEGELMAN, S., 1983, Dose-dependent elimination of propranolol and its major metabolites in humans. Journal of Pharmaceutical Sciences, 72, 725-732.
23. STRAKA, R. J., LALONDE, R. L., PIEPER, J. A., BOTTORFF, M. B. and MIRVIS, D. M., 1987, Nonlinear pharmacokinetics of unbound propranolol after oral administration. Journal of Pharmaceutical Sciences, 76, 521-524.
24. TAKAHASHI, H., OGAT, H., KANNO, S. and TAKEUCHI, H., 1990, Plasma protein binding of propranolol enantiomers as a major determinant of their stereoselective tissue distribution in rats. Journal of Pharmacology and Experimental Therapeutics, 252, 272-278.
25. WAGNER, J. G., 1988, Modeling first-pass metabolism. In Mathematical and Statistical Approach to Metabolism and Distribution of Chemicals and Drugs, edited by A. Pecile and A. Rescigno (New York: Plenum Press), pp. 129-149.
26. WALLE, T. and GAFFNEY, T. E., 1972, Propranolol metabolism in man and dog: mass spectrometric identification of six new metabolites. Journal of Pharmacology and Experimental Therapeutics, 182, 83-92.
27. WALLE, T., CONRADI, E. C., WALLE, U. K., FAGAN, T. C. and GAFFNEY, T. E., 1979, Propranolol glucuronide cumulation during long-term propranolol therapy: a proposed storage mechanism for propranolol. Clinical Pharmacology and Therapeutics, 26, 686-695.
28. WALLE,. T., CONRADI, E. C., WALLE, U. K., FAGAN, T. C. and GAFFNEY, T. E., 1980, 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol. Clinical Pharmacology and Therapeutics, 27, 22-31.
29. WALLE, T., WALLE, U. K. and OLANOFF, L. S., 1985, Quantitative account of propranolol metabolism in urine of normal man. Drug Metabolism and Disposition, 13, 204-209.
30. WOOD, A. J., CARR, K., VESTAL, R. E., BELCHER, S., WILKINSON, G. R. and SHAND, D. G., 1978, Direct measurement of propranolol bioavailability during accumulation to steady-state. British Journal of Clinical Pharmacology, 6, 345-350.